Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02925416 · ClinicalTrials.gov registry record · Phase 4
Safety of Either a Single or Two Intravenous Doses of Orbactiv in Participants With Acute Bacterial Skin and Skin Structure Infection
A Phase 4 study, sponsored by The Medicines Company.
- Completed
- Registry status
- Phase 4
- Development phase
- 22
- Enrollment target
NCT02925416 is a Phase 4 study that has completed, run by The Medicines Company. The registered enrollment target is 22 participants.
The verdict
NCT02925416, a Phase 4 study, has completed, sponsored by The Medicines Company.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 22 participants
- Enrollment target
Study Summary
The purpose of this study was to evaluate the safety and tolerability of two 1200 milligram (mg) intravenous (IV) infusions of oritavancin when administered one week apart.
Interventions
- DRUG Oritavancin
- DRUG Placebo (D5W)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2017-01-24 |
| Est. Completion | 2017-06-20 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02925416
The ClinicalTrials.gov registry entry for NCT02925416 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 22 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is The Medicines Company, which has 35 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Oritavancin is the first listed.
NCT02925416 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02925416 about?
NCT02925416 is a clinical study titled "Safety of Either a Single or Two Intravenous Doses of Orbactiv in Participants With Acute Bacterial Skin and Skin Structure Infection". The purpose of this study was to evaluate the safety and tolerability of two 1200 milligram (mg) intravenous (IV) infusions of oritavancin when administered one week apart.
What is the current status of trial NCT02925416?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 22 participants. The study started on 2017-01-24. Estimated completion is 2017-06-20.
What interventions are being tested in trial NCT02925416?
The interventions under investigation include: Oritavancin (DRUG), Placebo (D5W) (DRUG).
Who is sponsoring clinical trial NCT02925416?
This trial is sponsored by The Medicines Company, which has 35 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.